Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

SCYNEXIS, Inc.

SCYXNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.81
$0.00(0.00%)
U.S. Market is Open • 12:52

SCYNEXIS, Inc. Fundamental Analysis

SCYNEXIS, Inc. (SCYX) shows weak financial fundamentals with a PE ratio of -1.62, profit margin of -8.63%, and ROE of -54.26%. The company generates $0.0B in annual revenue with weak year-over-year growth of -97.33%.

Key Strengths

Cash Position97.16%
PEG Ratio0.06
Current Ratio5.75

Areas of Concern

ROE-54.26%
Operating Margin-11.81%
We analyze SCYX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -770.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-770.4/100

We analyze SCYX's fundamental strength across five key dimensions:

Efficiency Score

Weak

SCYX struggles to generate sufficient returns from assets.

ROA > 10%
-49.54%

Valuation Score

Excellent

SCYX trades at attractive valuation levels.

PE < 25
-1.62
PEG Ratio < 2
0.06

Growth Score

Weak

SCYX faces weak or negative growth trends.

Revenue Growth > 5%
-97.33%
EPS Growth > 10%
-1.31%

Financial Health Score

Excellent

SCYX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.06
Current Ratio > 1
5.75

Profitability Score

Weak

SCYX struggles to sustain strong margins.

ROE > 15%
-5426.10%
Net Margin ≥ 15%
-8.63%
Positive Free Cash Flow
No

Key Financial Metrics

Is SCYX Expensive or Cheap?

P/E Ratio

SCYX trades at -1.62 times earnings. This suggests potential undervaluation.

-1.62

PEG Ratio

When adjusting for growth, SCYX's PEG of 0.06 indicates potential undervaluation.

0.06

Price to Book

The market values SCYNEXIS, Inc. at 1.12 times its book value. This may indicate undervaluation.

1.12

EV/EBITDA

Enterprise value stands at 21.92 times EBITDA. This signals the market has high growth expectations.

21.92

How Well Does SCYX Make Money?

Net Profit Margin

For every $100 in sales, SCYNEXIS, Inc. keeps $-8.63 as profit after all expenses.

-8.63%

Operating Margin

Core operations generate -11.81 in profit for every $100 in revenue, before interest and taxes.

-11.81%

ROE

Management delivers $-54.26 in profit for every $100 of shareholder equity.

-54.26%

ROA

SCYNEXIS, Inc. generates $-49.54 in profit for every $100 in assets, demonstrating efficient asset deployment.

-49.54%

Following the Money - Real Cash Generation

Operating Cash Flow

SCYNEXIS, Inc. generates limited operating cash flow of $-28.25M, signaling weaker underlying cash strength.

$-28.25M

Free Cash Flow

SCYNEXIS, Inc. generates weak or negative free cash flow of $-28.25M, restricting financial flexibility.

$-28.25M

FCF Per Share

Each share generates $-0.67 in free cash annually.

$-0.67

FCF Yield

SCYX converts -98.21% of its market value into free cash.

-98.21%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.62

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.06

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.12

vs 25 benchmark

P/S Ratio

Price to sales ratio

11.75

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.06

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.75

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.54

vs 25 benchmark

ROA

Return on assets percentage

-0.50

vs 25 benchmark

ROCE

Return on capital employed

-0.81

vs 25 benchmark

How SCYX Stacks Against Its Sector Peers

MetricSCYX ValueSector AveragePerformance
P/E Ratio-1.6229.43 Better (Cheaper)
ROE-54.26%800.00% Weak
Net Margin-862.89%-20145.00% (disorted) Weak
Debt/Equity0.060.30 Strong (Low Leverage)
Current Ratio5.754.64 Strong Liquidity
ROA-49.54%-17936.00% (disorted) Weak

SCYX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SCYNEXIS, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

257.88%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

95.42%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

92.72%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ